Cabozantinib in Patients with Advanced Renal Cell Carcinoma Primary Refractory to First-line Immunocombinations or Tyrosine Kinase Inhibitors
- 19 February 2022
- journal article
- research article
- Published by Elsevier in European Urology Focus
- Vol. 8 (6) , 1696-1702
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Impact of Clinicopathological Features on Survival in Patients Treated with First-line Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors for Renal Cell Carcinoma: A Meta-analysis of Randomized Clinical TrialsEuropean Urology Focus, 2022
- Immune-based combinations for the treatment of metastatic renal cell carcinoma: a meta-analysis of randomised clinical trialsEuropean Journal of Cancer, 2021
- Complete response and renal cell carcinoma in the immunotherapy era: The paradox of good newsCancer Treatment Reviews, 2021
- Artificial Neural Networks as a Way to Predict Future Kidney Cancer Incidence in the United StatesClinical Genitourinary Cancer, 2021
- Pseudoprogression and hyperprogression during immune checkpoint inhibitor therapy for urothelial and kidney cancerWorld Journal of Urology, 2018
- Primary, Adaptive, and Acquired Resistance to Cancer ImmunotherapyCell, 2017
- RECIST 1.1—Update and clarification: From the RECIST committeeEuropean Journal of Cancer, 2016
- The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs—Part A: Renal, Penile, and Testicular TumoursEuropean Urology, 2016
- Targeted therapies and complete responses in first line treatment of metastatic renal cell carcinoma. A meta-analysis of published trialsCancer Treatment Reviews, 2014
- Heterogeneous drug target expression as possible basis for different clinical and radiological response to the treatment of primary and metastatic renal cell carcinoma: suggestions from bench to bedsideCancer and Metastasis Reviews, 2013